Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 8 citations in OpenAlex.
María Ángeles AbengozarCentro de Investigaciones Biológicas Margarita Salas, c/ Ramiro de Maeztu 9, CSIC, 28040 Madrid, Spain.
Nerea GaztelumendiDepartament de Biologia Cellular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.
Daniel CarbajoInstitut de Química Avançada de Catalunya (IQAC-CSIC), c/ Jordi Girona, 18-26, 08034 Barcelona, Spain.
Carme NoguésDepartament de Biologia Cellular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.ORCID 0000-0002-6361-8559
Luis RivasCentro de Investigaciones Biológicas Margarita Salas, c/ Ramiro de Maeztu 9, CSIC, 28040 Madrid, Spain.ORCID 0000-0002-2958-3233
Jean-Didier MaréchalDepartament de Química, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.ORCID 0000-0002-8344-9043
Miriam RoyoCentro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), c/ Jordi Girona 18-26, 08034 Barcelona, Spain.ORCID 0000-0001-5292-0819
Rosa M OrtuñoDepartament de Química, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallès, Spain.ORCID 0000-0001-7635-7354
Universitat Autònoma de Barcelona · ESCentro de Investigaciones Biológicas Margarita Salas · ESBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESInstitute of Advanced Chemistry of Catalonia · ESUniversity of Tolima · CO
Funding
Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina CB/06/01/0074Consejo Superior de Investigaciones Científicas PIE 201620E038Departament d'Empresa i Coneixement, Generalitat de Catalunya 2017-SGR-1439Departament d'Empresa i Coneixement, Generalitat de Catalunya 2017-SGR-503Ministerio de Ciencia e Innovación CTQ2016-77978.RMinisterio de Ciencia e Innovación MAT2017-86357-C3-3-RMinisterio de Ciencia e Innovación SAF2014-60138-RMinisterio de Ciencia, Innovación y Universidades RTI2018-093831-B-I00Subdirección General de Redes y Centros de Investigación Cooperativa-FEDER RICET RD16/0027/0010
6 · The paper itself
Abstract
A new family of hybrid β,γ-peptidomimetics consisting of a repetitive unit formed by a chiral cyclobutane-containing
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Hybrid Cyclobutane/Proline-Containing Peptidomimetics: The Conformational Constraint Influences Their Cell-Penetration Ability. · full record | OpenQuestion